AML Video Channel

Explore the latest insights and summaries from experts in AML.

Treatment Landscape

University of Colorado Division of Hematology

2024 Updates in AML

FEATURING Christine McMahon
  • 751 views
  • April 16, 2024
  • 6

Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

FEATURING Talha Badar
  • 725 views
  • July 16, 2024
  • 4

Rush University Medical Center

Is Post-HSCT Maintenance the SOC for AML?

FEATURING Mark Levis
  • 302 views
  • May 29, 2024
  • 4

Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Option

FEATURING Harry P. Erba
  • 898 views
  • April 17, 2024
  • 7

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell Transplant

FEATURING Robert Peter Gale
  • 520 views
  • February 15, 2024
  • 2

Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

FEATURING Talha Badar
  • 2,207 views
  • January 24, 2024
  • 14

Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

FEATURING Hagop Kantarjian
  • 423 views
  • May 31, 2024
  • 3

Icahn School of Medicine at Mount Sinai

BPDCN: Current and Future Directions

FEATURING Naveen Pemmaraju
  • 488 views
  • May 31, 2024
  • 2

Indy Hematology Review

R/R AML: Current, Emerging, and Targeted Therapies

FEATURING Rami Komrokji
  • 350 views
  • April 22, 2024
  • 3

Memorial Sloan Kettering Cancer Center

Key Updates in AML, MDS, & MF From ASH

FEATURING Aaron Goldberg
  • 300 views
  • May 2, 2024
  • 4

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 7+3 Is No Longer the Standard of Care

FEATURING Tapan Kadia
  • 673 views
  • September 11, 2024
  • 7

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

FEATURING Farhad Ravandi
  • 384 views
  • March 25, 2024
  • 2

Rush University Medical Center

Allo-HSCT Conditioning Regimens: Current Status and Future Directions

FEATURING Claudio Brunstein
  • 264 views
  • May 24, 2024

UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

FEATURING Anand Patel
  • 384 views
  • March 20, 2024
  • 3

Vanderbilt University Medical Center (VUMC)

Prevention and Management of Post-SCT Relapse in Acute Leukemias

FEATURING Andrew Jallouk
  • 257 views
  • July 18, 2024
  • 6

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

State of the Art: Role of Maintenance Therapy in AML

FEATURING Zeba Aziz
  • 230 views
  • February 15, 2024

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Highlights in Heme Malignancies

  • 456 views
  • September 23, 2024
  • 2

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

FEATURING Catherine Lai
  • 536 views
  • March 11, 2024
  • 3

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Management of AML in Older Patients

FEATURING Farhad Ravandi
  • 199 views
  • August 29, 2024

Rush University Medical Center

What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

FEATURING Ehab Atallah
  • 231 views
  • May 29, 2024
  • 1

University of Miami Sylvester Comprehensive Cancer Center

Current and Emerging Treatment Approaches for Patients With AML or MDS

  • 132 views
  • August 26, 2024

Indy Hematology Review

Current & Emerging Therapies for AML and MDS

FEATURING Rami Komrokji
  • 141 views
  • May 3, 2024

Vanderbilt University Medical Center (VUMC)

Pre-Transplant Management of High-Risk AML

FEATURING Kateryna Fedorov
  • 97 views
  • July 18, 2024
  • 2

Moffitt Cancer Center

Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient

FEATURING Onyee Chan
  • 109 views
  • March 5, 2024

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Acute Promyelocytic Leukemia: Risk Stratification and New Treatment Modalities

  • 83 views
  • February 16, 2024
  • 1

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

How I Manage Febrile Neutropenia in Patients With Cancer

FEATURING Şiran Keske
  • 65 views
  • February 21, 2024
  • 1

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 3+7 is the SOC Induction Therapy for AML

FEATURING Ant Uzay
  • 56 views
  • August 15, 2024
  • 1

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A 50-Year Personal Perspective on the Treatment of AML

  • 167 views
  • February 21, 2024

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Future Directions in AML: Optimizing Doublets and Triplets to Improve Efficacy and Maintain Safety

FEATURING Naval Daver
  • 58 views
  • February 15, 2024

Therapeutic Agents

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

FEATURING Alexander Perl
  • 723 views
  • March 3, 2024
  • 4

Indy Hematology Review

R/R AML: Current, Emerging, and Targeted Therapies

FEATURING Rami Komrokji
  • 350 views
  • April 22, 2024
  • 3

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

FEATURING Catherine Lai
  • 536 views
  • March 11, 2024
  • 3

Icahn School of Medicine at Mount Sinai

BPDCN: Current and Future Directions

FEATURING Naveen Pemmaraju
  • 488 views
  • May 31, 2024
  • 2

Rush University Medical Center

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

FEATURING Eric Bhaimia
  • 339 views
  • May 24, 2024

Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

FEATURING Richard Childs
  • 750 views
  • April 18, 2024
  • 5

Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignancies

FEATURING Ruemu Birhiray
  • 907 views
  • April 16, 2024
  • 5

Moffitt Cancer Center

Using Transplant in Patients With p53 Mutant MDS or AML

FEATURING Hany Elmariah
  • 329 views
  • March 7, 2024
  • 5

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 7+3 Is No Longer the Standard of Care

FEATURING Tapan Kadia
  • 673 views
  • September 11, 2024
  • 7

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

FEATURING Farhad Ravandi
  • 384 views
  • March 25, 2024
  • 2

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML

FEATURING Wei-Ying Jen
  • 246 views
  • June 26, 2024
  • 2

University of Miami Sylvester Comprehensive Cancer Center

Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable

  • 185 views
  • March 18, 2024
  • 1

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML

FEATURING Gautam Borthakur
  • 150 views
  • July 1, 2024
  • 2

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Management of AML in Older Patients

FEATURING Farhad Ravandi
  • 199 views
  • August 29, 2024

Rush University Medical Center

What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

FEATURING Ehab Atallah
  • 231 views
  • May 29, 2024
  • 1

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp

FEATURING Emanuele Angelucci
  • 216 views
  • July 23, 2024
  • 1

Yale Cancer Center

The Role of Hypomethylating Agent Maintenance in AML

FEATURING Rory Shallis
  • 117 views
  • July 1, 2024

University of Miami Sylvester Comprehensive Cancer Center

Current and Emerging Treatment Approaches for Patients With AML or MDS

  • 132 views
  • August 26, 2024

Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo

FEATURING Esther Oliva
  • 152 views
  • March 22, 2024

Indy Hematology Review

Current & Emerging Therapies for AML and MDS

FEATURING Rami Komrokji
  • 141 views
  • May 3, 2024

Yale Cancer Center

Targeting Apoptosis in Leukemia: Lessons and Challenges

FEATURING Marina Konopleva
  • 110 views
  • March 15, 2024

Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors

FEATURING Joshua Zeidner
  • 68 views
  • June 26, 2024

Icahn School of Medicine at Mount Sinai

Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias

FEATURING Omar Abdel-Wahab
  • 57 views
  • July 2, 2024

UNC Lineberger Comprehensive Cancer Center

Strategies for Managing Toxicities of Oral Oncolytics in Leukemia

  • 57 views
  • August 28, 2024

Moffitt Cancer Center

Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient

FEATURING Onyee Chan
  • 109 views
  • March 5, 2024

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 3+7 is the SOC Induction Therapy for AML

FEATURING Ant Uzay
  • 56 views
  • August 15, 2024
  • 1

Louisville Hematology Highlights

New Directions in CAR-T: Targeting Novel Antigens

FEATURING Robert Emmons
  • 146 views
  • February 27, 2024
  • 2

Louisville Hematology Highlights

Is a Bigger Induction "Hammer" Necessarily Better in Today's Stem Cell Transplantation?

FEATURING William Tse
  • 110 views
  • February 27, 2024
  • 1

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Future Directions in AML: Optimizing Doublets and Triplets to Improve Efficacy and Maintain Safety

FEATURING Naval Daver
  • 58 views
  • February 15, 2024

Diagnostics & Biomarkers

Moffitt Cancer Center

Using Transplant in Patients With p53 Mutant MDS or AML

FEATURING Hany Elmariah
  • 329 views
  • March 7, 2024
  • 5

University of Miami Sylvester Comprehensive Cancer Center

Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable

  • 185 views
  • March 18, 2024
  • 1

UChicago Medicine 12th International Clinical Cancer Genomics Conference

MDS and AML: Implementation of Guideline-Driven Germline Genetic Evaluation Criteria

FEATURING Lauren Banaszak
  • 399 views
  • May 28, 2024
  • 4

Icahn School of Medicine at Mount Sinai

BPDCN: Current and Future Directions

FEATURING Naveen Pemmaraju
  • 488 views
  • May 31, 2024
  • 2

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

FEATURING Farhad Ravandi
  • 384 views
  • March 25, 2024
  • 2

Rush University Medical Center

What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

FEATURING Ehab Atallah
  • 231 views
  • May 29, 2024
  • 1

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Use and Interpretation of Molecular Genetics in Blood Cancer

  • 350 views
  • March 4, 2024
  • 2

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Practical Approach to MRD Monitoring in AML: Assessing Treatment Efficacy and Relapse Risk

FEATURING Tapan Kadia
  • 104 views
  • September 11, 2024

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

AML: Diagnosis, Trends, and Approaches

FEATURING Mary-Beth Percival
  • 82 views
  • August 14, 2024

Icahn School of Medicine at Mount Sinai

Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias

FEATURING Omar Abdel-Wahab
  • 57 views
  • July 2, 2024

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Acute Promyelocytic Leukemia: Risk Stratification and New Treatment Modalities

  • 83 views
  • February 16, 2024
  • 1

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Pediatric AML: Diagnosis and Risk Stratification

FEATURING Nihal Karadaş
  • 179 views
  • February 16, 2024

Disease Overview

Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

FEATURING Robert Peter Gale
  • 3,523 views
  • February 26, 2024
  • 19

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

AML: Diagnosis, Trends, and Approaches

FEATURING Mary-Beth Percival
  • 82 views
  • August 14, 2024

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Pediatric AML: Diagnosis and Risk Stratification

FEATURING Nihal Karadaş
  • 179 views
  • February 16, 2024

Case Studies

Indy Hematology Review

R/R AML: Current, Emerging, and Targeted Therapies

FEATURING Rami Komrokji
  • 350 views
  • April 22, 2024
  • 3

Tisch Cancer Institute at Mount Sinai

Leukemia Tumor Board: 25 y/o With FLT3-TKD+ AML

FEATURING Justine Anderson
  • 87 views
  • May 6, 2024

Vanderbilt University Medical Center (VUMC)

Age Limits in Stem Cell Transplants and Cell Therapy

FEATURING Reena Jayani
  • 66 views
  • July 22, 2024

UNC Lineberger Comprehensive Cancer Center

Strategies for Managing Toxicities of Oral Oncolytics in Leukemia

  • 57 views
  • August 28, 2024

Moffitt Cancer Center

Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient

FEATURING Onyee Chan
  • 109 views
  • March 5, 2024